<?xml version="1.0" encoding="UTF-8"?>
<p>The potential for application of phage products, such as endolysins, should be investigated. Pulmonary CoVs will likely be a clinical challenge for many years to come. Viral pandemics from CoVs and emerging pathogens are inevitable in our globalized world with interconnected societies, travel, and commerce. We require to be well prepared for long-term management of COVID-19 and for the next pandemic, exploring and establishing new avenues to treat bacterial pathogens commonly observed in secondary infections. To avert an emerging healthcare crisis due from COVID-1 and antibiotic-resistance of secondary infections; medical interventions employing phage products or phage therapy itself might be our most promising options.</p>
